Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Down 5.1% – Here’s What Happened

Ascendis Pharma A/S (NASDAQ:ASND)’s share price traded down 5.1% during trading on Thursday . The stock traded as low as $126.38 and last traded at $127.98. 108,859 shares changed hands during trading, a decline of 74% from the average session volume of 416,135 shares. The stock had previously closed at $134.87.

Analyst Ratings Changes

Several brokerages recently weighed in on ASND. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Wedbush reissued an “outperform” rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a report on Friday, November 15th. TD Cowen reduced their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Stifel Nicolaus increased their target price on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Finally, Oppenheimer reduced their price target on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a report on Friday, November 15th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $192.07.

Ascendis Pharma A/S Stock Down 1.4 %

The company has a market cap of $8.07 billion, a PE ratio of -16.47 and a beta of 0.65. The firm’s fifty day simple moving average is $132.95 and its 200-day simple moving average is $133.55.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB acquired a new position in shares of Ascendis Pharma A/S in the third quarter valued at approximately $30,000. Groupama Asset Managment purchased a new stake in Ascendis Pharma A/S in the 3rd quarter valued at about $60,000. GAMMA Investing LLC grew its holdings in Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 214 shares during the period. Signaturefd LLC boosted its holdings in shares of Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 80 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in shares of Ascendis Pharma A/S by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 143 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.